Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Announces Warrant Exercise
Ablynx NV (Ablynx) announced that an additional 61,812 common shares have been issued by the Company in exchange for EUR 329,619.51 as the result of the exercise of warrants by some employees and consultants of the Company. As a result of this transaction, Ablynx has 43,779,197 shares outstanding.
Latest Developments for Ablynx NV
Latest Key Developments in Biotechnology
- Alkermes PLC announces new drug application for Aripiprazole Lauroxil
- ICON PLC raises FY 2014 EPS outlook; narrows FY 2014 revenue outlook to a range in line with analysts' estimates
- GW Pharmaceuticals Plc announces Epidiolex receives orphan designation from European Medicines Agency for the Treatment of Dravet Syndrome
- Proteon Therapeutics Inc announces pricing of Initial Public Offering
- Share this
- Digg this